Clinical Trials Logo

Biomarkers clinical trials

View clinical trials related to Biomarkers.

Filter by:

NCT ID: NCT05196516 Recruiting - COVID-19 Clinical Trials

Biomarkers for Post-COVID Conditions

Start date: January 13, 2022
Phase:
Study type: Observational

The COVID-19 infection affects humans differently. While some recover quickly and fully, others develop serious illnesses and late complications. The term late complications describe symptoms that last for 12 weeks or longer after COVID-19 infection is detected. The aim of the present project is to investigate whether it is possible to identify genetic factors that occur more frequently in people suffering from COVID-19 late complications than in those who do not develop late complications. The investigators aim to develop a genetic profile that identifies individuals at high risk for late complications of COVID-19. Number and nature of late complications will be analyses to identify patterns in the incidence of late complications associated with certain genetic traits. The study is designed as a case-control study and is expected to include 500 subjects between 18 and 65 years of age who at least 12 weeks ago tested positive for COVID-19; 250 who suffer from late complications and 250 who have fully recovered.

NCT ID: NCT05181423 Recruiting - Biomarkers Clinical Trials

Identification of Noninvasive Biomarkers for Neonates Undergoing Abdominal Surgery

Start date: January 1, 2021
Phase:
Study type: Observational

To identify the potential serum and radiological biomarkers with regard to neonates undergoing abdominal surgery, and to further evaluate the prognostic value of these markers.

NCT ID: NCT05138731 Recruiting - Biomarkers Clinical Trials

Metabolomics Profiling of Coronary Heart Disease

Start date: October 1, 2020
Phase:
Study type: Observational

This study sought to assess the diagnostic and prognostic values of metabolomics in coronary artery disease(CAD).

NCT ID: NCT05138692 Completed - Biomarkers Clinical Trials

Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury

Start date: October 1, 2000
Phase:
Study type: Observational [Patient Registry]

After written consent from next-of-kin patients with severe traumatic brain injury was included from the neurointensive care unit (NICU) at Sahlgrenska university hospital, Gothenburg. Blood and CSF samples were collected during the initial 3 weeks after trauma. 1 year after trauma patients were assessed according to Glasgow outcome scale (GOS), NIHSS and Barthels. 10-15 years after trauma a repeated evaluation according to GOS was performed by telephone. Different biomarkers such as Neurofilament light, Glial fibrillary acidic protein and Tau among others, was analyzed from serum and CSF samples. Further patients were explored Apolipoprotein-E genetype (APOE). The investigators hypothesize that higher biomarkers concentrations and positive test for this gene relate to worse outcome 1-year and 10-15 years after trauma. Further that these biomarkers and genetic marker further have prognostic value on outcome 1-year and 10-15 years after trauma. Finally, the investigators want to explore the concentrations dynamics of these biomarkers in serum and CSF in the acute phase after trauma.

NCT ID: NCT05095324 Active, not recruiting - Sepsis Clinical Trials

The Biomarker Prediction Model of Septic Risk in Infected Patients

Start date: September 7, 2021
Phase:
Study type: Observational [Patient Registry]

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to an infection. Sepsis is associated with high mortality because of the complex mechanisms. In China, the mortality of sepsis in ICU was up to 35.5%. As a major and urgent global public health challengeļ¼Œsepsis is hard to treat because of the complexion and highly heterogeneous in clinical manifestation. The early diagnosis and stratification of the infection is very important. If we can identify the patients who may developed into the sepsis, the therapeutic regimen was not only antibiotic, but also included stable the vascular endothelial cellsļ¼Œregulation of coagulation function and protection of organ functions. Biomarkers have an important place in sepsis because they are strictly related to the organ damage. Each organ has its own specific biomarkers, and these biomarkers will change according to the severity of the disease. So the investigators want to find the difference of biomarkers of each organ in patients from infection to spesis.

NCT ID: NCT05088005 Completed - Biomarkers Clinical Trials

Prognostic Biomarkers in CO Poisoning

Start date: January 1, 2020
Phase:
Study type: Observational

Mitochondrial and oxidative stress participate in the pathogenic mechanisms of carbon monoxide (CO)-induced toxicity. Thus, serum indicators of mitochondrial and oxidative stress could be useful for predicting neurocognitive prognosis of post-CO poisoning. This prospective observational study of consecutive patients requiring hyperbaric oxygen therapy (HBO2) for acute CO poisoning measured serum biomarkers of mitochondrial (growth differentiation factor 15 [GDF15]; fibroblast growth factor 21 [FGF21]) and oxidative (8-Oxo-2'-deoxyguanosine [8-OHdG] and malondialdehyde [MDA]) stresses at arrival at the emergency department (0 h), and at 24 h and 7 days after HBO2 completion. We evaluated neurocognitive outcomes using the Global Deterioration Scale (GDS; favorable [1-3 points] or poor [4-7 points] outcomes).

NCT ID: NCT04989478 Completed - Fasting Clinical Trials

Postprandial Metabolism in Healthy Young Subjects

PoMet
Start date: August 16, 2021
Phase: N/A
Study type: Interventional

This study aims to describe the dynamic changes in nutritional biomarkers in the blood during the postprandial period, i.e. the time period from the last meal and into the fasting state. In total 36 healthy, young men and women will be recruited in Bergen, Norway, and after receiving a standardized breakfast meal they will consume only water for the next 24 hours.

NCT ID: NCT04976426 Not yet recruiting - Diabetes Mellitus Clinical Trials

Establishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic Nephropathy

Start date: January 1, 2022
Phase:
Study type: Observational

Diabetic kidney disease(DKD) is a leading cause of chronic kidney disease and end-stage renal disease across the world. Early identification of DKD is vitally important for the effective prevention and control of it. However, the available indicators are doubtful in the early diagnosis of DKD. This study aims to develop a novel system of multidimensional network biomarkers (MDNBs) to estimating early diabetic nephropathy, and further validating the performance of the novel systemin in prediction of the risk for early diabetic nephropathy by a nested case-control study.

NCT ID: NCT04885738 Not yet recruiting - Biomarkers Clinical Trials

The Value of FeNO in Predicting Airway Eosinophilic Inflammation

FeNO-Eos
Start date: May 25, 2021
Phase:
Study type: Observational [Patient Registry]

To investigate and compare the value of FeNO, blood Eos, serum TIgE in predicting the airway eosinophilic inflammationin chronic cough, asthma and COPD.

NCT ID: NCT04880252 Completed - Cognitive Decline Clinical Trials

Neuropsychological Indicators of SCD Progression

SCD-CI
Start date: May 1, 2019
Phase:
Study type: Observational

Some patients with subjective cognitive decline (SCD) progress to neurocognitive disorders (NCD), whereas others remain stable; however, the neuropsychological determinants of this progression have not been identified. The investigators objective was to examine baseline neuropsychological indicators that could discriminate between people in whom the SCD progressed to a mild or major NCD and people in whom the SCD remained stable. The investigators retrospectively included patients consulting for SCD at a university medical center's memory center (Amiens, France) and who had undergone three or more neuropsychological assessments at least 6 months apart. The relationship between domain-specific scores and the global cognitive score (GCS, as a function of final status (stable SCD vs. progression toward a mild or major NCD)) was examined using a generalized linear mixed model.